Kindred Biosciences, Inc. announced that it has developed a technology to extend canine antibody half-life by up to three-fold. A patent application for this technology has been filed. The study comprised 12 dogs, including four groups with various modifications incorporating KindredBio technology and one wild type canine antibody as control. Half-life extension was observed in all dogs across all groups other than the wild type, with the magnitude of extension over native antibody ranging from two to three-fold. Additional studies to further differentiate between lead molecules and expand sample size are planned for 2020. Half-life extension technologies have the potential to improve therapeutic performance in numerous ways. Reduced dosing frequency and/or amount of dosing can lead to improved patient convenience and compliance. It can also substantially lower the cost of goods and enhance profitability and market positioning. In addition, higher drug concentration using the same dose and dosing interval as the parent antibody can result in extended drug exposure and potentially improved efficacy. KindredBio's canine biologics pipeline includes treatments in development for atopic dermatitis, inflammatory bowel diseases and parvovirus.